Skip to main content
S 3020 110th Congress Senate Health Commerce Defective products Fines (Penalties) Government Operations and Politics Government publicity Law Medical supplies Medical technology Product safety Science, Technology, Communications

Food and Drug Administration Accountability and Transparency Act

Introduced: May 15, 2008 See on congress.gov
This bill died when the 110th Congress ended
It never became law before the 110th Congress (2007–2008) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 15, 2008
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 15, 2008
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Food and Drug Administration Accountability and Transparency Act - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to publish in the Federal Register postmarket surveillance plans for medical devices, unless such information is exempted under the Freedom of Information Act.

Subjects medical device manufacturers that fail to comply with postmarket surveillance requirements to civil monetary penalties. Requires the Secretary to take into consideration whether the manufacturer is making efforts toward correcting the violation in determining the amount of the civil penalty.

Authorizes the Secretary to order notification of health personnel and other relevant persons if a violation of postmarket surveillance requirements of a device presents an unreasonable risk of substantial harm to the public health, such notification is necessary to eliminate such risk, and no more practicable means is available to eliminate such risk.

What's happening now May 15, 2008

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3020: Food and Drug Administration Accountability and Transparency Act. 110th Congress. Open America. https://openamerica.io/bill/110-S-3020/
MLA
"S. 3020: Food and Drug Administration Accountability and Transparency Act." 110th Congress, 2026, Open America, https://openamerica.io/bill/110-S-3020/.
Bluebook (legal)
S. 3020, 110th Cong. (2026), https://openamerica.io/bill/110-S-3020/.
Markdown link
[S. 3020: Food and Drug Administration Accountability and Transparency Act](https://openamerica.io/bill/110-S-3020/)
Report a problem